Background
==========

*BRAF*is a member of the RAF family of kinases that acts upstream of the MEK1/2 kinases in response to RAS signals. Activating mutations in *BRAF*have been reported in 5--15% of colorectal carcinomas (CRC), with by far the most common mutation being a 1796T to A transversion leading to a V600E substitution \[[@B1]-[@B3]\]. The *BRAF*V600E hotspot mutation is strongly associated with the microsatellite instability (MSI+) phenotype but is mutually exclusive with *KRAS*mutations \[[@B4]-[@B7]\]. Interestingly, *BRAF*mutations are found only in MSI+ sporadic tumors that result from aberrant *MLH1*promoter methylation and do not occur in MSI+ tumors from hereditary non-polyposis colorectal cancer (HNPCC) patients \[[@B5],[@B8]-[@B10]\], thus providing a convenient discriminator between sporadic and familial cases. The majority of MSI+ sporadic tumors belong to a larger CRC group referred to as the CpG island methylator phenotype (CIMP+) that is characterised by widespread hypermethylation of CpG islands located with gene promoter regions \[[@B11]\]. Both MSI+ and CIMP+ tumors are thought to arise from large hyperplastic polyps and serrated adenomas \[[@B12],[@B13]\] and recent work has demonstrated a high frequency of *BRAF*mutations in these lesions \[[@B7],[@B14],[@B15]\].

Although the positive association with MSI+ and inverse association with *KRAS*mutation have been well documented, little is known about the other properties of tumors with *BRAF*mutation. In the present study we analysed for *BRAF*V600E mutations in a consecutive series of 275 CRCs that were well characterised for the major pathological and molecular features of this disease. Our results demonstrate that oncogenic *BRAF*mutation occurs preferentially within a subgroup of CRCs that have distinctive features. It could therefore be used as a convenient marker for the further characterisation of these tumors, particularly in relation to their prognosis and response to adjuvant chemotherapy.

Results
=======

Figure [1A](#F1){ref-type="fig"} shows representative Fluorescent-SSCP results for the screening of *BRAF*mutations in this CRC series, while Figure [1B](#F1){ref-type="fig"} shows DNA sequencing confirmation of the 1799T to A transversion resulting in the V600E mutation. The overall frequency of *BRAF*mutation was 8.4% (23/275), comparing favourably with frequencies of 9--11% reported for other large studies of this tumor type \[[@B6],[@B16],[@B17]\]. The mean age of patients with and without *BRAF*mutation was identical (Table [1](#T1){ref-type="table"}). Strong associations were observed between *BRAF*mutation and tumor origin in the proximal side of the large bowel, poor histological grade, mucinous appearance and the presence of infiltrating lymphocytes. Higher frequencies of *BRAF*mutation were also observed in females and in node negative tumors but these did not reach significance.

![(A) Representative F-SSCP gel used to detect *BRAF*mutationsin colorectal cancer. WT, wild-type; M, mutation. (B) DNA sequencing gel resultconfirms the presence of a 1799T to A mutation giving rise to the V600E mutation.](1476-4598-5-2-1){#F1}

###### 

Associations between *BRAF*mutation and clinicopathological features of colorectal cancer.

  **Feature (n) ^a^**        ***BRAF*wild-type (%)**   ***BRAF*mutation (%)**   ***P***
  -------------------------- ------------------------- ------------------------ ----------
  Total (275)                252 (92)                  23 (8)                   
                                                                                
  Age (yrs)                  68.4 ± 13.0               68.4 ± 20.7              NS
                                                                                
  Gender                                                                        
   Men (132)                 124 (94)                  8 (6)                    
   Women (100)               87 (87)                   13 (13)                  0.068
                                                                                
  Infiltrating lymphocytes                                                      
   Negative (199)            190 (95)                  9 (5)                    
   Positive (21)             11 (52)                   10 (48)                  \<0.0001
                                                                                
  Nodal involvement                                                             
   Negative (128)            115 (90)                  13 (10)                  
   Positive (70)             66 (94)                   4 (6)                    NS
                                                                                
  Tumor site                                                                    
   Proximal (93)             79 (85)                   14 (15)                  
   Distal (126)              122 (97)                  4 (3)                    0.0015
                                                                                
  Histological grade                                                            
   Well/moderate (140)       133 (95)                  7 (5)                    
   Poor (29)                 22 (76)                   7 (24)                   0.0006
                                                                                
  Mucinous                                                                      
   Negative (159)            150 (94)                  9 (6)                    
   Positive (27)             20 (74)                   7 (26)                   0.0005

^a^Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 cases and mucinous appearance in 89 cases.

*BRAF*mutations showed no association with *TP53*mutations and were mutually exclusive with the presence of *KRAS*mutations (Table [2](#T2){ref-type="table"}). In contrast, *BRAF*mutations were approximately 10-fold more frequent in MSI+ and CIMP+ tumors compared to tumors without these phenotypes. A strong association was also seen with methylation of the *MLH1*gene promoter and in particular with methylation of its proximal region. We have previously examined the methylation status of 7 different CpG islands in this CRC series \[[@B18]\]. The mean number of these methylated sites was 3-fold higher in tumors with *BRAF*mutation compared to those without (2.6 ± 1.7 *vs*0.8 ± 1.0; *P*\< 0.001). Multivariate analysis revealed that MSI+ was the only significant independent predictor of *BRAF*mutation (RR = 6.3, 95%CI \[1.2--32.3\]; *P*= 0.028) in a model that included CIMP+, tumor site, histological grade, presence of infiltrating lymphocytes and mucinous appearance.

###### 

Associations between *BRAF*mutation and molecular features of colorectal cancer.

  **Feature (n) ^a^**      ***BRAF*wild-type (%)**   ***BRAF*mutation (%)**   ***P***
  ------------------------ ------------------------- ------------------------ ----------
  Total (275)              252 (92)                  23 (8)                   
                                                                              
  MSI                                                                         
   negative (204)          195 (96)                  9 (4)                    
   positive (31)           19 (61)                   12 (39)                  \<0.0001
                                                                              
  Methylation status                                                          
   CIMP- (150)             145 (97)                  5 (3)                    
   CIMP+ (42)              31 (74)                   11 (26)                  \<0.0001
                                                                              
   *MLH1*distal region                                                        
   Negative (168)          159 (95)                  9 (5)                    
   Positive (24)           17 (71)                   7 (29)                   \<0.0001
                                                                              
   *MLH1*proximal region                                                      
   Negative (179)          169 (94)                  10 (6)                   
   Positive (13)           7 (54)                    6 (46)                   \<0.0001
                                                                              
  *KRAS*                                                                      
   Wild-type (156)         134 (86)                  22 (14)                  
   Mutant (93)             93 (100)                  0 (0)                    \<0.0001
                                                                              
  *TP53*                                                                      
   Wild-type (183)         166 (91)                  17 (9)                   
   Mutant (66)             62 (94)                   4 (6)                    NS

^a^Data was unavailable for MSI status in 40 cases, methylation status in 83 cases, *KRAS*mutation in 26 cases and *TP53*mutation in 26 cases

We next examined whether the characteristic features of tumors with *BRAF*mutation were still apparent following stratification into MSI and CIMP phenotypes. Although the statistical power of this subgroup analysis was limited, the morphological features of infiltrating lymphocytes, poor histological grade and mucinous appearance were clearly associated with *BRAF*mutation regardless of tumor MSI status (Table [3](#T3){ref-type="table"}). Similarly, these features were each more common in tumors with *BRAF*mutation in both the CIMP- and CIMP+ subgroups (Table [4](#T4){ref-type="table"}). Similar to previous observations in a separate CRC cohort \[[@B20]\], the frequency of *KRAS*mutation was lower in MSI+ compared to MSI- tumors (*P*= 0.034; Table [3](#T3){ref-type="table"}), while the frequency of *TP53*mutation was also considerably lower in MSI+ tumors with wildtype *BRAF*than in MSI- tumors with wildtype *BRAF*(*P*= 0.014).

###### 

Clinicopathological and molecular features of *BRAF*mutant colorectal cancers stratified according to microsatellite instability status.

                           **MSI-**                    **MSI+**                               
  ------------------------ ------------- ------------- ---------- ------------- ------------- ------
  Age (years)              68.5 ± 12.6   58.2 ± 26.5   NS         67.5 ± 16.8   76.1 ± 10.9   NS
  Females                  39            44            NS         63            75            NS
  TILS + ^a^               3             44            0.0004     28            60            0.08
  Node negative            62            62            NS         81            89            NS
  Proximal site            36            67            0.05       72            89            NS
  Poor grade               15            40            0.12       25            56            0.11
  Mucinous                 12            53            0.05       6             44            0.04
  CIMP+                    15            50            0.03       40            88            0.03
  Dist. *MLH1*methylated   7             12            NS         40            75            0.10
  Prox. *MLH1*methylated   1             0             NS         33            75            0.06
  *KRAS*mutant             43            0             0.008      21            0             0.12
  *TP53*mutant             29            11            NS         5             18            NS

^a^Tumor-infiltrating lymphocytes

###### 

Clinicopathological and molecular features of *BRAF*mutant colorectal cancers stratified according to methylator phenotype status.

                           **CIMP-**                   **CIMP+**                               
  ------------------------ ------------- ------------- ----------- ------------- ------------- -------
  Age (years)              68.3 ± 13.5   71.0 ± 11.0   NS          71.7 ± 11.8   65.4 ± 26.3   NS
  Females                  37            60            NS          42            45            NS
  TILS +                   2             40            0.008       17            45            0.06
  Node negative            63            60            NS          65            82            NS
  Proximal site            35            60            NS          74            80            NS
  Poor grade               13            66            0.05        20            40            NS
  Mucinous                 9             25            NS          25            45            NS
  MSI+                     6             20            NS          19            64            0.01
  Dist. *MLH1*methylated   3             0             NS          42            64            NS
  Prox. *MLH1*methylated   0             0             NS          23            55            0.05
  *KRAS*mutant             43            0             0.06        55            0             0.001
  *TP53*mutant             26            0             NS          29            20            NS

Discussion
==========

The *BRAF*V600E mutation has already been proposed as a convenient marker to discriminate between MSI+ tumors that are sporadic or HNPCC in origin \[[@B5],[@B8]-[@B10]\]. This is a very important issue for population-based screening programs that aim to identify CRC associated with the HNPCC syndrome. Compared to the analysis of *MLH1*promoter methylation, mutation at the *BRAF*V600E hotspot is relatively simple to detect using DNA sequencing, RFLP or the SSCP method used in the present work (Figure [1](#F1){ref-type="fig"}).

Similar to other studies \[[@B4],[@B5],[@B10],[@B16],[@B17]\] we observed *BRAF*mutation frequencies of 4% in MSI- tumors and 39% in MSI+ tumors (Table [1](#T1){ref-type="table"}). The highest frequencies were seen in tumors showing methylation of the *MLH1*promoter proximal region (46%) and in tumors with infiltrating lymphocytes (48%). *BRAF*mutation frequencies of up to 70--80% have been reported in sporadic MSI+, CIMP+ and *MLH1*-methylated CRC and polyps \[[@B7],[@B8],[@B15],[@B16]\]. For reasons that are still unclear, *BRAF*mutations are approximately 5--10-fold more frequent in tumors that have characteristic features of sporadic MSI+ (ie. *MLH1*methylated) and CIMP+ phenotypes. These include proximal colon location, poor differentiation, mucinous histology and infiltrating lymphocytes \[[@B13],[@B19],[@B20]\]. Interestingly however, in the present study *BRAF*mutations never occurred in association with *KRAS*mutation, were present in only 3% of CIMP- tumors and showed no association with *TP53*mutation (Table [2](#T2){ref-type="table"}). The observation that *BRAF*mutations occur only very rarely in HNPCC-related MSI+ CRC demonstrates that defective DNA mismatch repair is not involved in causing this genetic alteration.

In order to determine whether the characteristic clinicopathological features of tumors with *BRAF*mutation were due to their close association with MSI+ and CIMP+, we stratified tumours according to these phenotypes. Despite having only 9 MSI-/*BRAF*mutant and 5 CIMP-/*BRAF*mutant tumors, the results showed that associations between *BRAF*mutation and the morphological properties of tumor-infiltrating infiltrating lymphocytes, poor histological grade and mucinous phenotype were retained (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

The frequencies of *BRAF*mutation observed in MSI- (4%) and MSI+ (39%) tumors in the present study compare favourably (5% and 52%, respectively) to those reported recently in another large, population-based study \[[@B17]\]. Although *BRAF*mutations are much more frequent in MSI+ tumors, the comparative rarity of this phenotype means that a considerable proportion occur in MSI- tumors. In the present study, 43% of all *BRAF*mutations occurred in MSI- tumors compared to 48% in the study by Samowitz *et al*\[[@B17]\]. *BRAF*mutations were reported to show prognostic significance in MSI- but not in MSI+ CRC \[[@B17]\]. The lack of follow-up information on CRC patients in the current study and the small number of *BRAF*mutations (n = 21) meant that we were unable to evaluate the prognostic significance of *BRAF*mutation according to MSI status.

Conclusion
==========

Findings from the present study and from previous work indicate that *BRAF*mutation is likely to be a convenient marker for the identification of a subset of CRCs with distinctive clinical, pathological and molecular features and which may originate in hyperplastic polyps and serrated adenomas \[[@B7],[@B14],[@B15]\]. In view of the strong associations between *BRAF*mutation and specific pathological (site, grade, mucinous, infiltrating lymphocytes) and molecular (methylated MSI+, CIMP+, wildtype *KRAS*) features, it will be interesting in future studies to determine the predictive significance of this marker for response to adjuvant therapies in CRC.

Methods
=======

The 275 colorectal tumors investigated in this study were obtained from the Colorectal Unit of the Royal Adelaide Hospital. These were snap frozen in liquid nitrogen within 20--40 min after resection and stored at -70°C prior to extraction of DNA. Clinical data available for this series included patient age, sex and family history of CRC. Only one case was confirmed as HNPCC-related. Pathological data included nodal involvement, tumor site, histological grade, mucinous appearance and the presence of infiltrating lymphocytes. Evaluation of MSI+ \[[@B21]\], CIMP+ \[[@B18]\], *KRAS*mutation \[[@B22]\] and *TP53*mutation \[[@B23]\] were performed as described previously by our group. Mutations in exon 15 of *BRAF*including the V600E hotspot were detected using the PCR primer sequences reported earlier \[[@B1]\], the F-SSCP method \[[@B22],[@B23]\] and confirmed by direct sequencing.

Statistical analyses were performed using SPSS Version 12.0 (Chicago, Illinois, USA). Associations between *BRAF*mutation and clinical, pathological or molecular features were evaluated using Fisher\'s exact or Pearson\'s chi-squared tests as appropriate. Multivariate analysis was performed using binary logistic regression with *BRAF*mutation as the dependent variable.
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